(News Bulletin 247) – OSE Immuno won more than 4% on the Paris Stock Exchange on Thursday after completing a progress report on its monoclonal antibody OSE-127, developed in partnership with Servier.
In a press release, the biotechnology company reports the online publication in the medical journal ‘The Journal of Immunology’ of positive Phase 1 clinical results on OSE-127/S95011, showing the product’s good safety and tolerability profile.
According to Nicolas Poirier, CEO of OSE, the publication of the article, which is among the most read on the site, attests to the value of the Phase 1 results.
Developed in partnership with Servier, OSE-127/S95011 is currently the subject of a Phase 2 study in ulcerative colitis and another in Sjögren’s syndrome, an autoimmune disease characterized by mouth and eye dryness.
Recruitment of patients in the Phase 2a trial in primary Sjögren’s syndrome has been completed and the first results are expected in the first half of 2023.
Nicolas Poirier says he is ‘confident’ that these studies will position OSE-127 as a new ‘best-in-class’ treatment for patients with these two chronic inflammatory diseases.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
